HuMax AXL ADC - Genmab

Drug Profile

HuMax AXL ADC - Genmab

Alternative Names: Axl-specific Antibody-drug Conjugate; HuMax®-AXL-ADC

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genmab; Seattle Genetics
  • Developer Genmab
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 22 Dec 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater) in United Kingdom (unspecified route) (NCT02988817)
  • 22 Dec 2016 Preclinical trials in Solid tumours in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top